CYP4AA2 Inhibitors
The chemical class of CYP4AA2 inhibitors consists mainly of azole antifungal drugs and selective serotonin reuptake inhibitors (SSRIs), each with distinct mechanisms of action for inhibiting the enzyme activity. Azole antifungals, including ketoconazole, miconazole, fluconazole, clotrimazole, voriconazole, itraconazole, posaconazole, and econazole, exert their inhibitory effects by binding to the heme iron of the enzyme's active site, thereby interfering with substrate binding and metabolism. These compounds block the enzymatic activity of CYP4AA2, preventing the metabolism of endogenous and exogenous substrates.
Similarly, SSRIs such as fluoxetine, fluvoxamine, paroxetine, and sertraline inhibit CYP4AA2 activity by competitively binding to the enzyme's active site, thereby reducing its ability to metabolize substrates. By competing with substrates for binding at the enzyme's active site, SSRIs effectively inhibit CYP4AA2-mediated metabolism, leading to enzyme inhibition and altered metabolic pathways.
Overall, these inhibitors represent valuable tools for studying the role of CYP4AA2 in various physiological and pathological processes, as well as potential targets for conditions associated with dysregulated CYP4AA2 activity. Further research into the development of novel inhibitors and their mechanisms of action could lead to new insights into CYP4AA2-mediated pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole is an azole antifungal agent that inhibits CYP4AA2 by blocking its active site, thus preventing the metabolism of substrates and leading to enzyme inhibition. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $65.00 $157.00 | 2 | |
Miconazole, another azole antifungal, inhibits CYP4AA2 by binding to the heme iron of the enzyme's active site, thereby interfering with substrate binding and metabolism. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Fluconazole is a triazole antifungal drug that inhibits CYP4AA2 by blocking the enzyme's active site, thus preventing the metabolism of substrates and leading to enzyme inhibition. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $41.00 $56.00 | 6 | |
Clotrimazole, an azole antifungal, inhibits CYP4AA2 by binding to the heme iron of the enzyme's active site, thereby interfering with substrate binding and metabolism. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Itraconazole, a triazole antifungal drug, inhibits CYP4AA2 by binding to the heme iron of the enzyme's active site, thereby interfering with substrate binding and metabolism. | ||||||
Posaconazole | 171228-49-2 | sc-212571 | 1 mg | $353.00 | 7 | |
Posaconazole is a triazole antifungal agent that inhibits CYP4AA2 by blocking its active site, thus preventing the metabolism of substrates and leading to enzyme inhibition. | ||||||
Econazole | 27220-47-9 | sc-279013 | 5 g | $240.00 | ||
Econazole, an azole antifungal, inhibits CYP4AA2 by binding to the heme iron of the enzyme's active site, thereby interfering with substrate binding and metabolism. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $312.00 | 9 | |
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that inhibits CYP4AA2 by competing for binding at the enzyme's active site, thereby reducing its ability to metabolize substrates. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $315.00 | 1 | |
Fluvoxamine, another SSRI, inhibits CYP4AA2 by competitively binding at the enzyme's active site, thus reducing its ability to metabolize substrates and leading to enzyme inhibition. | ||||||
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
Paroxetine, an SSRI antidepressant, inhibits CYP4AA2 by competing for binding at the enzyme's active site, thereby reducing its ability to metabolize substrates and leading to enzyme inhibition. | ||||||